interferon induced protein 44 likeGenealiases: C1orf29 · GS3686 · TLDC5B
Q-omics provides the consensus-scored IFI44L profile across patient tissues and cancer cell-line models. IFI44L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IFI44L is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, IFI44L RNA expression shows 15,498 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where IFI44L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFI44L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFI44L survival associations across molecular data types. IFI44L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFI44L RNA expression–survival associations across cancer types. High IFI44L expression shows unfavorable associations in KIRP, UCEC and UVM, but favorable associations in SKCM, KIRC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IFI44L RNA expression.
This table summarizes IFI44L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IFI44L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFI44L shows lower tumor expression in KICH, LUSC and THCA and higher tumor expression in HNSC, KIRC and BLCA. The HNSC box plot shows higher IFI44L RNA expression in tumor versus normal tissue (log2 FC = +2.771, t-test p < 0.001).
This table shows molecular features associated with IFI44L in patient tissues and cancer cell lines. In patient samples, IFI44L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IFI44L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
